Skip to main content
Back to all tickers

Biodexa Pharmaceuticals Plc (BDRX) stock forecast & analysis

2.40

NasdaqCM · USDDelayed by 15 minutes

Up: +0.04, +1.5%

3 analyses

Use Arrow keys to explore price history; Home and End jump to the oldest and newest points
Price history for BDRX.US from 2026-05-15 to 2026-11-13 with 1 analysis run marked; public runs are shown as stance-colored dots (Bullish, Bearish, or Neutral) and gated runs as a lock icon (sign in to read). Each marker is a link to sign in.BullishBearishNeutralLocked · sign in to read

Open
2.42
Previous close
2.37
Day range
2.36 – 2.42
52-week range
2.28 – 357.60
Volume (shares)
9.15K
Net assets
Not available
Expense ratio
Not available
Shares outstanding
524.24K
P/E ratio
Not available
Dividend yield
0.00%
Beta
1.27
Market cap
1.26M
Market Scanner’s AI analysis of Biodexa Pharmaceuticals Plc (BDRX), updated October 2026: BDRX's Phase 3 Serenta trial enrollment milestone and accelerated timeline contrasted with persistent unprofitability and a strong bearish technical trend.

This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Biodexa Pharmaceuticals Plc (BDRX) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.

Summary

BDRX's Phase 3 Serenta trial enrollment milestone and accelerated timeline contrasted with persistent unprofitability and a strong bearish technical trend.

Recent analyses for BDRX covered the company's progress in its Phase 3 Serenta trial for Familial Adenomatous Polyposis (FAP), including reaching a 100-patient enrollment milestone and an accelerated analysis timeline. This clinical development was discussed alongside the company's ongoing financial performance, which has consistently shown negative gross profits and net incomes, and a significant downward trend in its stock price relative to key moving averages.

BDRX news & sentiment

News coverage highlighted positive developments in BDRX's Phase 3 Serenta trial, including reaching a key enrollment milestone and an accelerated analysis timeline. Broader market news noted volatility in European equities traded in the US, but this was not specific to BDRX. No social media discussion was covered in the provided notes.

BDRX technical picture

The stock price has shown a strong downward trend, trading significantly below key moving averages with bearish momentum indicated by MACD readings. Technical indicators presented mixed signals regarding oversold conditions and buying pressure, with the price action generally sitting near the lower Bollinger Band.

Fundamentals

The company has consistently reported negative gross profits and net losses over the past four fiscal years, with negative operating cash flow. As of June 30, 2026, total debt was zero, and the company held $3.23 million in cash, with current and quick ratios indicating sufficient short-term assets.

Factors discussed — upside

  • Phase 3 Serenta trial reached 100-patient enrollment milestone.
  • Accelerated timeline for key analysis of the Serenta trial.
  • Zero total debt reported as of June 30, 2026.
  • Current and quick ratios indicate sufficient short-term assets to cover liabilities.

Factors discussed — risks

  • Persistent negative gross profits and net incomes from 2022-2025.
  • Stock price significantly below 50-day and 200-day simple moving averages.
  • Strong downward trend indicated by 30-day and 91-day price changes.
  • Negative operating cash flow for the past four fiscal years.
  • High volatility indicated by a Beta of 1.283.
  • Clinical trial progress
  • Financial performance
  • Technical indicators
  • Biotechnology industry

Summary updated .

BDRX technical indicators

Common technical indicators for BDRX, computed from its daily closing prices.

IndicatorValueReading
50-day simple moving average4.56Price below
10-day exponential moving average2.63Price below
Relative strength index (14-day)32.76Neutral
MACD line (12/26/9)-0.6482Above its signal line
Bollinger bands (20-day, 2σ)1.89 – 4.17Price inside the bands

BDRX stock forecast — AI outlook

The most recent historical sample analysis of BDRX recorded this AI decision distribution. Get a current verdict.

Buy 10%Hold 20%Sell 70%

As of

Analyses

Historical, AI-generated samples of past BDRX.US analyses — one per day, shown for context, not current guidance. Newer reports are locked; sign in to read them or generate a fresh one.

CaseDescriptionDate
  • Bearish

    The company reports negative profitability and significant losses over the trailing twelve months and for the fiscal year 2025. While the 7-day stock change is positive, longer-term trends and key moving averages indicate a bearish outlook.

    Sign in to open the full 2026-09-14 BDRX.US analysis

Frequently asked questions

What is the bull case for Biodexa Pharmaceuticals Plc?
The bull case for BDRX centers on progress in its Phase 3 Serenta trial, marked by reaching a 100-patient enrollment milestone and an accelerated analysis timeline. Additionally, the company reported zero total debt as of June 30, 2026, and its current and quick ratios indicate sufficient short-term assets to cover liabilities.
What are the risks for Biodexa Pharmaceuticals Plc?
Risks for BDRX include persistent negative gross profits and net incomes from 2022 through 2025, alongside negative operating cash flow over the past four fiscal years. The stock's technical indicators show a strong downward trend, with the price significantly below key moving averages and high volatility noted.
Is Biodexa Pharmaceuticals Plc bullish or bearish?
Recent AI analyses of Biodexa Pharmaceuticals Plc examined factors on both sides. Discussed upside: The bull case for BDRX centers on progress in its Phase 3 Serenta trial, marked by reaching a 100-patient enrollment milestone and an accelerated analysis timeline. Additionally, the company reported zero total debt as of June 30, 2026, and its current and quick ratios indicate sufficient short-term assets to cover liabilities. Discussed risks: Risks for BDRX include persistent negative gross profits and net incomes from 2022 through 2025, alongside negative operating cash flow over the past four fiscal years. The stock's technical indicators show a strong downward trend, with the price significantly below key moving averages and high volatility noted. These are descriptive observations, not a recommendation.
What is the latest sentiment on Biodexa Pharmaceuticals Plc?
News coverage highlighted positive developments in BDRX's Phase 3 Serenta trial, including reaching a key enrollment milestone and an accelerated analysis timeline. Broader market news noted volatility in European equities traded in the US, but this was not specific to BDRX. No social media discussion was covered in the provided notes.
What is the Biodexa Pharmaceuticals Plc (BDRX) stock forecast?
Market Scanner publishes historical AI analysis samples rather than a live forecast. The most recent sample for Biodexa Pharmaceuticals Plc (BDRX), dated 2026-09-14, recorded an AI decision distribution of Buy 10%, Hold 20%, and Sell 70%. It is a dated historical sample shown for context, not current guidance.
What is the Biodexa Pharmaceuticals Plc (BDRX) stock prediction for 2026?
Market Scanner does not make price predictions for 2026. As of 2026-09-14, its most recent historical sample analysis of Biodexa Pharmaceuticals Plc (BDRX) recorded an AI decision distribution of Buy 10%, Hold 20%, and Sell 70%. Newer analyses are available after sign-in.
How does Market Scanner analyse Biodexa Pharmaceuticals Plc?
Every analysis of Biodexa Pharmaceuticals Plc runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for Biodexa Pharmaceuticals Plc?

The bull case for BDRX centers on progress in its Phase 3 Serenta trial, marked by reaching a 100-patient enrollment milestone and an accelerated analysis timeline. Additionally, the company reported zero total debt as of June 30, 2026, and its current and quick ratios indicate sufficient short-term assets to cover liabilities.

What are the risks for Biodexa Pharmaceuticals Plc?

Risks for BDRX include persistent negative gross profits and net incomes from 2022 through 2025, alongside negative operating cash flow over the past four fiscal years. The stock's technical indicators show a strong downward trend, with the price significantly below key moving averages and high volatility noted.

Is Biodexa Pharmaceuticals Plc bullish or bearish?

Recent AI analyses of Biodexa Pharmaceuticals Plc examined factors on both sides. Discussed upside: The bull case for BDRX centers on progress in its Phase 3 Serenta trial, marked by reaching a 100-patient enrollment milestone and an accelerated analysis timeline. Additionally, the company reported zero total debt as of June 30, 2026, and its current and quick ratios indicate sufficient short-term assets to cover liabilities. Discussed risks: Risks for BDRX include persistent negative gross profits and net incomes from 2022 through 2025, alongside negative operating cash flow over the past four fiscal years. The stock's technical indicators show a strong downward trend, with the price significantly below key moving averages and high volatility noted. These are descriptive observations, not a recommendation.

What is the latest sentiment on Biodexa Pharmaceuticals Plc?

News coverage highlighted positive developments in BDRX's Phase 3 Serenta trial, including reaching a key enrollment milestone and an accelerated analysis timeline. Broader market news noted volatility in European equities traded in the US, but this was not specific to BDRX. No social media discussion was covered in the provided notes.

What is the Biodexa Pharmaceuticals Plc (BDRX) stock forecast?

Market Scanner publishes historical AI analysis samples rather than a live forecast. The most recent sample for Biodexa Pharmaceuticals Plc (BDRX), dated 2026-09-14, recorded an AI decision distribution of Buy 10%, Hold 20%, and Sell 70%. It is a dated historical sample shown for context, not current guidance.

What is the Biodexa Pharmaceuticals Plc (BDRX) stock prediction for 2026?

Market Scanner does not make price predictions for 2026. As of 2026-09-14, its most recent historical sample analysis of Biodexa Pharmaceuticals Plc (BDRX) recorded an AI decision distribution of Buy 10%, Hold 20%, and Sell 70%. Newer analyses are available after sign-in.

How does Market Scanner analyse Biodexa Pharmaceuticals Plc?

Every analysis of Biodexa Pharmaceuticals Plc runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.

Read the methodology

Bundles used
gemini-low-v2

Run a fresh BDRX.US analysis

Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.

Or read 3 earlier reports



Most analyzed tickers